GM-CSF clinical trials

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

This study looks at a new drug, galinpepimut-S, for people with a type of blood cancer called Acute Myeloid Leukaemia (AML) who are in remission. It compares the new drug to standard treatments to see if it helps people live longer.